RxDoctor Payments Data

Michael Faber, DO

Internal Medicine · Warren, MINPI 1245325927

Payments from drug & device makers

$1,311in general payments, 2019–2025

Across 80 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$337
  • Lilly USA, LLC$190
  • Boehringer Ingelheim$153
  • Idorsia Pharmaceuticals US Inc$96
  • Kiniksa Pharmaceuticals, Ltd.$73
  • GSK$69
  • plus $394 from 15 others

What the payments were for

  • Food & beverage$1,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,311 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$62,983
Medicare patients
158
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin119$142,071
JanuviaSitagliptin Phosphate65$75,684
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$70,940
OzempicSemaglutide42$69,583
RybelsusSemaglutide16$42,485
EliquisApixaban38$42,444
TrulicityDulaglutide20$40,013
XareltoRivaroxaban20$30,915
LyricaPregabalin11$8,882
LinzessLinaclotide15$7,882
Incruse ElliptaUmeclidinium Bromide14$6,510
Levothyroxine Sodium290$4,075
Atorvastatin Calcium259$2,905
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,873
Metoprolol Succinate178$2,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$153$142,071119 claims
Novo NordiskOzempic, Rybelsus$337$112,06858 claims
GSKTrelegy Ellipta, Incruse Ellipta$69$77,449100 claims
MerckJanuvia$26$75,68465 claims
PfizerEliquis, Lyrica$43$51,32649 claims
Lilly USA, LLCTrulicity$190$40,01320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →